Bristol-Myers Squibb’s (BMY) Opdivo is a programmed death-1 (or PD-1) inhibitor that is already approved by the FDA and the European Medicines Agency (or EMA) for two cancer indications: melanoma and ...

Patients experienced a 38% reduction in the risk of disease progression or death when treated with Opdivo plus Yervoy versus Opdivo monotherapy across all lines of therapy at median 47 months of ...

Bristol-Myers Squibb, a global biopharmaceutical company, announced that part 2 of the phase 3 CheckMate -227 trial did not meet the primary endpoint of overall survival (OS) with Opdivo (nivolumab) ...